Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Assets: 2015-2024

Historic Current Assets for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $38.7 million.

  • Seres Therapeutics' Current Assets fell 29.35% to $51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.5 million, marking a year-over-year decrease of 29.35%. This contributed to the annual value of $38.7 million for FY2024, which is 77.95% down from last year.
  • Per Seres Therapeutics' latest filing, its Current Assets stood at $38.7 million for FY2024, which was down 77.95% from $175.4 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Current Assets ranged from a high of $303.6 million in FY2021 and a low of $38.7 million during FY2024.
  • Moreover, its 3-year median value for Current Assets was $175.4 million (2023), whereas its average is $136.3 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 168.27% in 2020, then slumped by 77.95% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Current Assets stood at $268.8 million in 2020, then grew by 12.97% to $303.6 million in 2021, then slumped by 35.85% to $194.8 million in 2022, then dropped by 9.94% to $175.4 million in 2023, then crashed by 77.95% to $38.7 million in 2024.